NHS Caution on Mounjaro as Thousands Get 'Key Notice' About Shots

Starting Fresh in the New Year

With the arrival of January, individuals often establish fresh wellness and physical activity targets, such as aiming to reduce body weight. Consistent physical activity, trips to the gym, and a well-rounded, nutrient-rich eating plan play essential roles in boosting general well-being and supporting the removal of surplus weight. Yet, for certain individuals, these approaches might fall short.

Some pharmaceutical options that promote weight reduction could suit select people, though they are typically intended for those with type 2 diabetes or individuals who have faced challenges in losing weight solely through dietary and exercise changes. These treatments act as helpful aids rather than exclusive solutions for those unable to manage weight on their own.

Understanding GLP-1 Agonists

GLP-1 agonists include substances like tirzepatide and semaglutide, commonly known by names such as Mounjaro, Ozempic, or Wegovy. They get prescribed to individuals dealing with type 2 diabetes or to support ongoing weight control in specific adults. These drugs operate by decreasing the speed at which stomach contents are processed, simulating intestinal hormones to control blood glucose and curb hunger, as noted by the Mirror.

Projections from the end of 2023 indicate that numerous hundreds of thousands, potentially exceeding half a million, in the UK rely on Mounjaro (tirzepatide) for personal weight management. Some sources estimate the combined users of Mounjaro and Wegovy at 1.5 to 2.5 million. Nevertheless, under 220,000 individuals anticipate access via the NHS in the coming three years because of stringent criteria.

NHS Advisory for Eligible Users

For those meeting the requirements and receiving prescriptions from their GP, a crucial NHS notification demands attention. It mainly concerns individuals also using additional drugs, such as the birth control pill and Hormone Replacement Therapy (HRT).

A 'vital alert' appears on the NHS site, targeting those receiving injections alongside the contraceptive pill or HRT. The health authority warns that specific injections can reduce the pill's and HRT's potency.

The message states: 'Numerous individuals currently employ weight reduction drugs such as Tirzepatide (Mounjaro) or Semaglutide (Ozempic, Wegovy, Rybelsus) – for managing diabetes or personal weight loss. These work in part by delaying stomach emptying, which may influence how effectively other medications, like the contraceptive pill or HRT tablets, get taken in by the body.'

Impact on Oral Contraceptives

Tirzepatide (Mounjaro) might weaken the efficacy of any oral birth control, encompassing the Progesterone-Only Pill. The NHS recommends:

• Employ additional safeguards (such as condoms) during episodes of vomiting or diarrhea.
• Adhere to missed pill guidelines (refer to the patient leaflet included with your pill) if vomiting occurs within three hours of ingestion or diarrhea lasts over 24 hours.

The alert proceeds: 'Utilize supplementary protection (like condoms) when experiencing vomiting or diarrhea, and observe the missed dose instructions (check the patient leaflet with your pill) if vomiting happens soon after taking it or diarrhea persists beyond a day.'

Concerning Semaglutide and similar drugs, the NHS notes 'these seem not to decrease pill effectiveness.' Still, adverse reactions like vomiting or diarrhea could hinder pill absorption.

'Therefore, apply extra precautions (such as condoms) during vomiting or diarrhea, and follow missed pill protocols (see the patient leaflet for your pill) if vomiting occurs within three hours of consumption or diarrhea exceeds 24 hours,' the NHS suggests. 'For more details, visit: Patient Information GLP 1 Agonists And Contraception.'

The NHS clarifies that GLP-1 agonists do not disrupt non-oral birth control methods. Options like the coil (IUD), implant, or injectable contraception remain safe with these agonists. If contemplating a switch in birth control, consult your physician.

Pregnancy and Conception Considerations

The health service adds: 'GLP-1 agonists are unsuitable during pregnancy. Reliable contraception is vital while using these drugs. If pregnancy occurs during treatment, contact your doctor right away. Cease GLP-1 agonists a few weeks prior to trying to conceive.'

This applies when HRT incorporates progesterone pills, such as:

Concerns exist that drugs like Tirzepatide (Mounjaro) and Semaglutide might impair tablet uptake. The NHS cautions: 'This may result in unpredictable bleeding and could compromise uterine lining defense (raising endometrial cancer risk).'

'Reach out to your clinic to explore HRT or contraceptive choices while on weight loss medication.'

Health tracking apps like Shotlee can assist in overseeing progress during weight management efforts, ensuring users stay informed about their goals.